INBX

$97.01-$1.35 (-1.37%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$1.4B

15M shares

52-week range

$22.40 – $155.29

56% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change+$68.96

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$4M	+230.8%	$-9.23	$-11.67–$-6.80	—	1
2027	$57M	+1230.2%	$-6.53	$-8.25–$-4.81	—	1
2028	$131M	+129.6%	$-3.98	$-5.02–$-2.93	—	1
2029	$203M	+54.2%	$-2.73	$-3.45–$-2.01	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-2.28	$-2.28	+0.0%
2026-05-14	$-2.37	$-2.15	+9.3%
2026-03-19	$-2.08	$-2.11	-1.4%
2025-11-14	$-2.08	$-2.28	-9.6%
2025-08-13	$-2.92	$-1.85	+36.6%
2025-05-14	$-2.55	$-2.80	-9.8%
2025-03-17	$-2.88	$-3.09	-7.3%
2024-11-14	$-3.06

DCF fair valuemodel estimate

Intrinsic value

$0.73

Price

$97.01

Implied downside

-99%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
INBXInhibrx Biosciences Inc.	$98.36	+6.47%	$1.4B	—
AMLXAmylyx Pharmaceuticals, Inc.	$23.35	-1.18%	$2.6B	—
ATAIAtai Beckley Inc.	$7.23	+0.28%	$2.7B	—
CVACCureVac N.V.	$4.66	+0.00%	$1.0B	—
ELVNEnliven Therapeutics, Inc.	$57.92	-1.46%

Inhibrx Biosciences, Inc. Common Stock

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

www.inhibrx.com

Employees: 110
IPO / List date: May 28, 2024
HQ: LA JOLLA, CA

Held by traders on TradeandTell

No one on the platform currently holds INBX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	50,183	$3.4M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded INBX yet.

$INBX chatter on StockTwits

David Matuszak@Dmnaz23h
@Dh32602 not worried. Look at what $INBX has done. They sold off 1 drug to Sanofi for a couple billion while shareholders got paid and kept the NEWCO. They will probably do the same thing again. This company can do the same. It's a win win.
View on StockTwits ↗
Mike@Mike223322331d
$SLS MY TOP 10 HOLDINGS … 1 is ready to go WEN is moving -- told you about it long ago & the other day ... still expect $10-$12 offer with board then maybe negotiating it up to $13 ! I uncover Special Situation Stocks & asymmetrical plays … most work out … some don't … the key is proper risk management & diversification … Always remember: this is not financial advice … PLEASE, Do your own DD before buying anything ! I've called My #1 holding, SLS, the best asymmetrical investment I've found in my 43 yrs of investing ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! EXPECTED % RETURNS FROM MY AVG BUY PRICES ... 1) SLS 3,400%-4,950% 2) $RYAM 88% 3) $MNRO 27%-57% 4) PRTH 39%-56% 5) GFL 28%-35% 6) $INBX 228%-457% 7) ZIM 36% 8) DDI 32%-74% 9) CRTO 38%-48% 10) $WEN 49%-79% LIKE & FOLLOW if you found these ideas useful !!! FOLLOW me 👉 @Mike22332233 as I posted reports on each
View on StockTwits ↗
M@justiceforb_852d
$INBX first company to show OX40 agonism (106) improved ORR and increased CRs in a randomized trial compared with keytruda monotherapy. Ozekibart (109) is the floor for the company's value. Look forward to the Q4 update in HNSCC.
View on StockTwits ↗
chefboobyflay@chefboobyflayBullish3d
$INBX
View on StockTwits ↗
Mike@Mike223322334d
$SLS OK ... # 6 Someone asked for my top 10 Special Situation Stock holdings .... I've called $SLS the best asymmetrical investment I've found in my 43 years of investing ... It's the largest holding, by far, in an over $1.35 mil portfolio ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! Now #6 ... $INBX ... The interim Phase 2 data for INBRX-106 + KEYTRUDA combination was outstanding and achieved a cORR of 44.0% vs. 21.4% with KEYTRUDA alone ... Patents on MRK's $34 Bil a yr KEYTRUDA franchise will soon run out, but MRK can salvage that franchise, and re-start that patent clock!! .... $MRK will Buy INBRX-106 from INBX .... I just don't know if it will be for $3.5 B ($240/shr) or $7 B ($480) ... and I don't know if it's in 2 months or 6 months !! ... and you will still own the rest of INBX, which is worth just as much -- INBX has done spinoff deals like this in the past !! FOLLOW me 👉 @Mike22332233 for other HUGE profit stocks
View on StockTwits ↗
Terzman@TerzmanBullishAug 4
$INBX
View on StockTwits ↗
Jeff Lee@Barrington787Jul 28
$INBX what a total turd.
View on StockTwits ↗
BullStockpicks1@BullStockpicks1Jul 28
$INBX here is my updated analysis, huge opportunity https://x.com/bullstkpicks/status/2082077393825542436?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w
View on StockTwits ↗
Jeff Goldberg@MBWallingfordJul 24
$INBX head fake again?
View on StockTwits ↗
Terzman@TerzmanBullishJul 23
$INBX new loan facility is inbx way of giving big pharma 🖕🏾 for any low ball effort to play ball .. if you wanna play with it ya gotta pay for it .. load up
View on StockTwits ↗
M@justiceforb_85Jul 23
$INBX remains significantly undervalued. Look forward to INBRX-106 updates on PFS in HNSCC.
View on StockTwits ↗
Jeff Goldberg@MBWallingfordJul 15
$INBX 20 shares? Some kind of head fake.
View on StockTwits ↗
Chris T@The_DingaJul 10
@Mike22332233 @mike22332233 big $INBX selloff today. thoughts?
View on StockTwits ↗
Inner Child@InnerchildBearishJul 10
$MTEN Stop buying Mten this shit , go buy rather $JLHL $OMEX $CRMT $INBX Go long for tickers that actually pay, but be careful with JLHL it’s a Chineese / Asian, shit could go sideways, just like GDC.
View on StockTwits ↗
Jeff Goldberg@MBWallingfordJul 9
$INBX the stock is now acting like something is brewing. A bit more volume would confirm.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.